Eli Lilly Acquires Disarm Therapeutics in an Effort to Solve Axonal Degeneration

Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.